TGFBR2 and Patent ductus arteriosus: To explore this, we investigated the percentages of PDA patients who have loss‐of‐function mutations in TGFBR2. The TCGA and UT Southwestern (UTSW) databases demonstrate that such mutations are found in up to 7% of the PDA patients (Fig 6D).